Gyre Therapeutics (GYRE) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to -$24.6 million.
- Gyre Therapeutics' Enterprise Value fell 34145.93% to -$24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.6 million, marking a year-over-year decrease of 34145.93%. This contributed to the annual value of $8.4 million for FY2024, which is 32427.65% up from last year.
- As of Q3 2025, Gyre Therapeutics' Enterprise Value stood at -$24.6 million, which was down 34145.93% from -$17.0 million recorded in Q2 2025.
- Gyre Therapeutics' 5-year Enterprise Value high stood at $10.2 million for Q3 2024, and its period low was -$131.0 million during Q1 2021.
- In the last 5 years, Gyre Therapeutics' Enterprise Value had a median value of -$12.6 million in 2023 and averaged -$27.8 million.
- As far as peak fluctuations go, Gyre Therapeutics' Enterprise Value soared by 32427.65% in 2024, and later plummeted by 34145.93% in 2025.
- Quarter analysis of 5 years shows Gyre Therapeutics' Enterprise Value stood at -$49.4 million in 2021, then skyrocketed by 109.16% to $4.5 million in 2022, then tumbled by 182.57% to -$3.7 million in 2023, then soared by 324.28% to $8.4 million in 2024, then plummeted by 393.36% to -$24.6 million in 2025.
- Its last three reported values are -$24.6 million in Q3 2025, -$17.0 million for Q2 2025, and $6.3 million during Q1 2025.